Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Baxter
Express Scripts
Medtronic
Johnson and Johnson

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 5,968,825

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 5,968,825
Title: Antisense oligonucleotides complementary to the primary transcript of the human c-fes protooncogene
Abstract:The following description sets forth antisense (AS) oligonucleotides (ODNs) complementary to the primary transcript of the human c-fes protooncogene and their use to inactivate said transcript. All-trans retinoic acid (ATRA) is reported to be used as a differentiation inducer on cells pretreated with said AS-ODNs to induce apoptosis of leukemic blast cells.
Inventor(s): Ferrari; Sergio (Modena, IT), Manfredini; Rossella (Campogalliano, IT)
Assignee: Istituto Biochimico Italiano Giovanni Lorenzini S.P.A. (Milan, IT)
Application Number:08/859,389
Patent Claims:1. An antisense oligonucleotide complementary to the primary transcript of human c-fes protooncogene, which hybridizes to said primary transcript at a sequence spanning to the exon 2/intron 2 or the exon 3/intron 3 splice junction.

2. The antisense oligonucleotide of claim 1, which includes the sequence shown in SEQ ID NO:1 or SEQ ID NO:2.

3. The antisense oligonucleotide of claim 1, which is modified and stabilized to prolong its half-life.

4. The antisense oligonucleotide of claim 3, modified at its 3' or 5' end with a phosphorothionate derivative.

5. The antisense oligonucleotide of claim 3, wherein its internucleotide phosphate bridge is a methylphosphonate, phosphorothionate, phosphorodithionate, or phosphate ester group.

6. The antisense oligonucleotide of claim 3, which is complexed noncovalently with transeferrin-polylysine.

7. A method for inhibiting expression of c-fes protein in a cell comprising administering to the cell at least one antisense oligonucleotide complementary to the primary transcript of the human c-fes protooncogene, wherein said antisense oligonucleotide hybridizes with said primary transcript at a sequence spanning to the exon 2/intron 2 or the exon 3/intron 3-splice junction.

8. The method of claim 7, wherein said antisense oligonucleotide includes the sequence shown in SEQ ID NO:1 or SEQ ID NO:2.

9. The method of claim 7, further comprising administering to said cells all-trans retinoic acid to induce cell differentiation and apoptosis.

Details for Patent 5,968,825

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2016-05-20
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2016-05-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Harvard Business School
AstraZeneca
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.